CooperVision announced that its MyDay MiSight 1‑day contact lenses are now shipping to Australia and New Zealand, marking the brand’s first entry into the Asia‑Pacific market. The company also began deliveries to South Africa and Israel, extending the product’s availability beyond its earlier launches in Europe, the Middle East and Africa.
The Asia‑Pacific region is home to some of the world’s highest myopia prevalence rates, with projections that by 2050 half of the global population will be affected. Demand for convenient, evidence‑based myopia‑control solutions is therefore accelerating, making the new market entries a strategic move to capture a rapidly expanding customer base.
This launch is part of CooperVision’s broader global rollout strategy for the MyDay MiSight line, which combines the proven ActivControl technology of MiSight 1‑day with the premium silicone‑hydrogel comfort of MyDay lenses. By entering Australia, New Zealand, South Africa and Israel, the company is positioning itself to broaden its addressable market, tap high‑margin, high‑growth segments, and drive incremental revenue and market‑share gains in a key growth region.
Financially, the company’s myopia‑control segment has been a strong growth engine. MiSight lenses grew 37 % in Q4 2025, while overall revenue rose 6 % year‑over‑year in Q3 2025 and 3.2 % organically in Q4 2025. CooperVision’s Q1 2026 guidance projects revenue up 6.3 % and earnings per share up 12 % year‑over‑year, underscoring the momentum behind its expanding product portfolio.
Management highlighted the significance of the expansion. Chief Commercial Officer Debbie Olive said, “Myopia is a pressing health challenge of epic proportions, now affecting nearly one in three children worldwide. The growing availability and adoption of our myopia control contact lenses, including MyDay MiSight 1‑day, are helping drive a meaningful shift in pediatric eye care by supporting children’s vision today while helping protect their sight for the future.” Vice President Jennifer Lambert added, “The introduction of MyDay MiSight 1‑day into the Asia Pacific region marks an important milestone in our global efforts to make the latest in evidence‑based myopia control accessible to as many children as possible. As MiSight® products become available in more markets worldwide, CooperVision’s scale and focus are driving a shift in the paradigm, from simply correcting vision to actively controlling myopia progression.”
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.